GEMINA LABS LTD (8I7) - Total Assets
Based on the latest financial reports, GEMINA LABS LTD (8I7) holds total assets worth €1.11 Million EUR (≈ $1.30 Million USD) as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GEMINA LABS LTD cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
GEMINA LABS LTD - Total Assets Trend (2022–2025)
This chart illustrates how GEMINA LABS LTD's total assets have evolved over time, based on quarterly financial data. See what is GEMINA LABS LTD's book value for net asset value and shareholders' equity analysis.
GEMINA LABS LTD - Asset Composition Analysis
Current Asset Composition (January 2025)
GEMINA LABS LTD's total assets of €1.11 Million consist of 7.4% current assets and 92.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0.1% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how GEMINA LABS LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is GEMINA LABS LTD worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GEMINA LABS LTD's current assets represent 7.4% of total assets in 2025, a decrease from 97.1% in 2022.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 81.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GEMINA LABS LTD Competitors by Total Assets
Key competitors of GEMINA LABS LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
GEMINA LABS LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.03 | 0.09 |
| Quick Ratio | 0.01 | 0.03 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-6.20 Million | €-4.62 Million | €-3.74 Million |
GEMINA LABS LTD - Advanced Valuation Insights
This section examines the relationship between GEMINA LABS LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 392.59 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | €1.44 Million |
| Market Capitalization | $1.53 Million USD |
Valuation Analysis
Above Book Valuation: The market values GEMINA LABS LTD's assets above their book value (1.06x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: GEMINA LABS LTD's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for GEMINA LABS LTD (2022–2025)
The table below shows the annual total assets of GEMINA LABS LTD from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-01-31 | €1.44 Million ≈ $1.68 Million |
-1.24% |
| 2024-01-31 | €1.46 Million ≈ $1.70 Million |
-22.33% |
| 2023-01-31 | €1.87 Million ≈ $2.19 Million |
+32.03% |
| 2022-01-31 | €1.42 Million ≈ $1.66 Million |
-- |
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more